de Mello RA - Search Results

1

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis.

Aguiar PN Jr, Santoro IL, Tadokoro H, de Lima Lopes G, Filardi BA, Oliveira P, Mountzios G, de Mello RA. Aguiar PN Jr, et al. Among authors: de lima lopes g, de mello ra. Immunotherapy. 2016;8(4):479-88. doi: 10.2217/imt-2015-0002. Immunotherapy. 2016. PMID: 26973128 Review.

2

Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies.

de Mello RA, Costa BM, Reis RM, Hespanhol V. de Mello RA, et al. Recent Pat Anticancer Drug Discov. 2012 Jan;7(1):118-31. doi: 10.2174/157489212798357994. Recent Pat Anticancer Drug Discov. 2012. PMID: 21854359 Free article. Review.

3

Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study.

de Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, Almeida MI, Cunha J, Oliveira P, Hespanhol V, Reis RM. de Mello RA, et al. Tumour Biol. 2012 Oct;33(5):1341-8. doi: 10.1007/s13277-012-0382-7. Epub 2012 Mar 29. Tumour Biol. 2012. PMID: 22457050

4

EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study.

de Mello RA, Pires FS, Marques DS, Oliveira J, Rodrigues A, Soares M, Azevedo I, Peixoto A, Santos C, Pinto C, Hespanhol V, Teixeira MR, Amaro T, Queiroga H, Araújo A. de Mello RA, et al. Tumour Biol. 2012 Dec;33(6):2061-8. doi: 10.1007/s13277-012-0465-5. Epub 2012 Jul 29. Tumour Biol. 2012. PMID: 22843317

5

The impact of polymorphic variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the risk and prognosis of portuguese patients with non-small cell lung cancer.

de Mello RA, Ferreira M, Soares-Pires F, Costa S, Cunha J, Oliveira P, Hespanhol V, Reis RM. de Mello RA, et al. PLoS One. 2013 Sep 6;8(9):e72373. doi: 10.1371/journal.pone.0072373. eCollection 2013. PLoS One. 2013. PMID: 24039754 Free PMC article.

6

EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.

de Mello RA, Madureira P, Carvalho LS, Araújo A, O'Brien M, Popat S. de Mello RA, et al. Pharmacogenomics. 2013 Nov;14(14):1765-77. doi: 10.2217/pgs.13.177. Pharmacogenomics. 2013. PMID: 24192124 Review.

7

Immunotherapy and lung cancer: current developments and novel targeted therapies.

Domingues D, Turner A, Silva MD, Marques DS, Mellidez JC, Wannesson L, Mountzios G, de Mello RA. Domingues D, et al. Among authors: de mello ra. Immunotherapy. 2014;6(11):1221-35. doi: 10.2217/imt.14.82. Immunotherapy. 2014. PMID: 25496336 Review.

8

Nivolumab for advanced squamous cell lung cancer: what are the next steps?

de Mello RA, Pousa I, Pereira D. de Mello RA, et al. Lancet Oncol. 2015 Mar;16(3):234-5. doi: 10.1016/S1470-2045(15)70074-4. Epub 2015 Feb 20. Lancet Oncol. 2015. PMID: 25704436 No abstract available.

9

Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents.

Califano R, Morgillo F, De Mello RA, Mountzios G. Califano R, et al. Among authors: de mello ra. Ann Transl Med. 2015 Apr;3(6):81. doi: 10.3978/j.issn.2305-5839.2015.03.44. Ann Transl Med. 2015. PMID: 25992380 Free PMC article. Review.

10

Treating operable patients with gastric cancer: Macdonald's protocol versus adjuvant chemotherapy.

Aguiar PN Jr, Tadokoro H, Forones NM, de Mello RA. Aguiar PN Jr, et al. Among authors: de mello ra. Future Oncol. 2015;11(16):2247-9. doi: 10.2217/fon.15.141. Future Oncol. 2015. PMID: 26260801 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

110 results

Search Page

Filters